Department of Medical Biochemistry, Amsterdam Cardiovascular Sciences (ACS), Amsterdam University Medical Centers, University of Amsterdam, Room K1-110, Meibergdreef 15, 1105 AZ Amsterdam, The Netherlands.
Institute for Cardiovascular Prevention (IPEK), Ludwig Maximilians University, Pettenkoferstraße 8a & 9, Munich, Germany.
Eur Heart J. 2019 Jan 21;40(4):372-382. doi: 10.1093/eurheartj/ehy714.
The E3-ligase CBL-B (Casitas B-cell lymphoma-B) is an important negative regulator of T cell activation that is also expressed in macrophages. T cells and macrophages mediate atherosclerosis, but their regulation in this disease remains largely unknown; thus, we studied the function of CBL-B in atherogenesis.
The expression of CBL-B in human atherosclerotic plaques was lower in advanced lesions compared with initial lesions and correlated inversely with necrotic core area. Twenty weeks old Cblb-/-Apoe-/- mice showed a significant increase in plaque area in the aortic arch, where initial plaques were present. In the aortic root, a site containing advanced plaques, lesion area rose by 40%, accompanied by a dramatic change in plaque phenotype. Plaques contained fewer macrophages due to increased apoptosis, larger necrotic cores, and more CD8+ T cells. Cblb-/-Apoe-/- macrophages exhibited enhanced migration and increased cytokine production and lipid uptake. Casitas B-cell lymphoma-B deficiency increased CD8+ T cell numbers, which were protected against apoptosis and regulatory T cell-mediated suppression. IFNγ and granzyme B production was enhanced in Cblb-/-Apoe-/- CD8+ T cells, which provoked macrophage killing. Depletion of CD8+ T cells in Cblb-/-Apoe-/- bone marrow chimeras rescued the phenotype, indicating that CBL-B controls atherosclerosis mainly through its function in CD8+ T cells.
Casitas B-cell lymphoma-B expression in human plaques decreases during the progression of atherosclerosis. As an important regulator of immune responses in experimental atherosclerosis, CBL-B hampers macrophage recruitment and activation during initial atherosclerosis and limits CD8+ T cell activation and CD8+ T cell-mediated macrophage death in advanced atherosclerosis, thereby preventing the progression towards high-risk plaques.
E3 连接酶 CBL-B(Casitas B 细胞淋巴瘤-B)是 T 细胞活化的重要负调控因子,也在巨噬细胞中表达。T 细胞和巨噬细胞介导动脉粥样硬化,但它们在这种疾病中的调节机制在很大程度上尚不清楚;因此,我们研究了 CBL-B 在动脉粥样硬化形成中的作用。
与初始病变相比,人动脉粥样硬化斑块中 CBL-B 的表达在进展性病变中较低,并且与坏死核心面积呈负相关。20 周龄 Cblb-/-Apoe-/- 小鼠的主动脉弓(存在初始斑块的部位)斑块面积明显增加。在主动脉根部(含有进展性斑块的部位),病变面积增加了 40%,斑块表型发生了显著变化。由于细胞凋亡增加,坏死核心增大,以及 CD8+T 细胞增多,斑块中的巨噬细胞减少。Cblb-/-Apoe-/- 巨噬细胞表现出增强的迁移能力以及细胞因子产生和脂质摄取增加。CBL-B 缺乏增加了 CD8+T 细胞数量,这些细胞免受细胞凋亡和调节性 T 细胞介导的抑制作用的影响。Cblb-/-Apoe-/-CD8+T 细胞中 IFNγ 和颗粒酶 B 的产生增加,这引发了巨噬细胞的杀伤作用。在 Cblb-/-Apoe-/- 骨髓嵌合体中耗尽 CD8+T 细胞可挽救表型,表明 CBL-B 主要通过其在 CD8+T 细胞中的功能来控制动脉粥样硬化。
人斑块中 CBL-B 的表达在动脉粥样硬化进展过程中减少。作为实验性动脉粥样硬化中免疫反应的重要调节因子,CBL-B 在初始动脉粥样硬化过程中阻碍了巨噬细胞的募集和激活,并限制了 CD8+T 细胞的激活和 CD8+T 细胞介导的巨噬细胞死亡在晚期动脉粥样硬化中,从而阻止了向高危斑块的进展。